Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel liposomal - Luye Pharma Group

Next Previous
Drug Profile

Paclitaxel liposomal - Luye Pharma Group

Alternative Names: Liposomal paclitaxel - Luye Pharma Group; Lipusu; Paclitaxel Liposome for Injection

Latest Information Update: 15 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luye Pharma Group
  • Developer Luye Pharma Group; Nanjing Sike Pharmaceutical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 28 Sep 2021 Discontinued - Phase-II for Breast cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
  • 28 Dec 2020 Luye Pharma and AstraZeneca sign a Memorandum of Understanding (MOU) to collaborate in the cardiovascular and oncology fields using monascus, paclitaxel liposomal and bevacizumab biosimilar
  • 04 Oct 2016 No recent reports on development identified - Phase-II for Breast cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top